Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Advertisement

Nature

View all journals
Search
Log in

nature
search

Search

Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Nature Medicine (3)

Choose more journals

Article type Check one or more article types to show results from those article types only.

Research (2)
Amendments and Corrections (1)

Subject Check one or more subjects to show results from those subjects only.

Biomarkers
Cancer
Diseases
Health care
Medical research

Date Choose a date option to show results from those dates only.

Today
Last 7 days
Last 30 days
Last 12 months
Last 2 years
Last 5 years

Custom date range

Clear all filters

Sort by:

Relevance

Date published (new to old)

Date published (old to new)

Showing 1–3 of 3 results

Advanced filters: Author: Kees Hendricksen Clear advanced filters

Author Correction: High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial

Jeroen van Dorp
Christodoulos Pipinikas
Michiel S. van der Heijden
Amendments and Corrections17 Jul 2023
Nature Medicine

Volume: 30, P: 304
High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial

High-dose ipilimumab plus nivolumab in locoregionally advanced urothelial cancer led to a higher pathological complete response rate than low-dose ipilimumab in cohort 2. Presurgical absence of plasma (but not urinary) circulating tumor DNA correlated with clinical outcome.

Jeroen van Dorp
Christodoulos Pipinikas
Michiel S. van der Heijden
Research02 Feb 2023
Nature Medicine

Volume: 29, P: 588-592
Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial

Neoadjuvant immunotherapy combination in the NABUCCO trial elicits high pathological complete response rates in patients with locoregionally advanced (stage III) urothelial cancer and provides molecular biomarkers of treatment efficacy.

Nick van Dijk
Alberto Gil-Jimenez
Michiel S. van der Heijden
Research12 Oct 2020
Nature Medicine

Volume: 26, P: 1839-1844

Search

Search articles by subject, keyword or author

Show results from

Advanced search

Quick links

Explore articles by subject
Find a job
Guide to authors
Editorial policies

Nature.com

nature.com sitemap

About Nature Portfolio

About us
Press releases
Press office
Contact us

Discover content

Journals A-Z
Articles by subject
protocols.io
Nature Index

Publishing policies

Nature portfolio policies
Open access

Author & Researcher services

Reprints & permissions
Research data
Language editing
Scientific editing
Nature Masterclasses
Research Solutions

Libraries & institutions

Librarian service & tools
Librarian portal
Open research
Recommend to library

Advertising & partnerships

Advertising
Partnerships & Services
Media kits
Branded content

Professional development

Nature Awards
Nature Careers
Nature Conferences

Regional websites

Nature Africa
Nature China
Nature India
Nature Japan
Nature Middle East

Privacy Policy
Use of cookies
Legal notice
Accessibility statement
Terms & Conditions
Your US state privacy rights

© 2026 Springer Nature Limited